These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35244071)

  • 41. Chronic cholestatic diseases.
    Poupon R; Chazouillères O; Poupon RE
    J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease.
    Heurgué A; Vitry F; Diebold MD; Yaziji N; Bernard-Chabert B; Pennaforte JL; Picot R; Louvet H; Frémond L; Geoffroy P; Schmit JL; Cadiot G; Thiéfin G
    Gastroenterol Clin Biol; 2007 Jan; 31(1):17-25. PubMed ID: 17273128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study.
    Leuschner M; Holtmeier J; Ackermann H; Leuschner U
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1369-76. PubMed ID: 12468960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
    Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
    Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
    Kotb MA
    Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
    Lindor KD; Dickson ER; Jorgensen RA; Anderson ML; Wiesner RH; Gores GJ; Lange SM; Rossi SS; Hofmann AF; Baldus WP
    Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review.
    Li X; Liao M; Pan Q; Xie Q; Yang H; Peng Y; Li Q; Qu J; Chai J
    Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1116-1122. PubMed ID: 32649329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
    Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
    Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.
    Saffioti F; Gurusamy KS; Eusebi LH; Tsochatzis E; Davidson BR; Thorburn D
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011648. PubMed ID: 28350426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of primary biliary cholangitis prior to obeticholic acid availability.
    Durazzo M; Bonetto S; Fagoonee S; Morgando A; Pellicano R
    Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta-Analysis.
    Pedersen MR; Greenan G; Arora S; Murali AR; Mayo MJ
    Liver Transpl; 2021 Jun; 27(6):866-875. PubMed ID: 33185320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel Therapies on Primary Biliary Cirrhosis.
    Czul F; Levy C
    Clin Liver Dis; 2016 Feb; 20(1):113-30. PubMed ID: 26593294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    Wang H; Li Y; Pu X; Liang X; Tang R; Ma X
    J Gastroenterol; 2024 Jan; 59(1):66-74. PubMed ID: 37845416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.
    Neuman MG; Cameron RG; Haber JA; Katz GG; Blendis LM
    Liver; 2002 Jun; 22(3):235-44. PubMed ID: 12100574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.